# Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea & Vomiting (CINV) Prophylaxis

> **NCT03478605** · PHASE2 · UNKNOWN · sponsor: **Blokhin's Russian Cancer Research Center** · enrollment: 130 (estimated)

## Conditions studied

- Emesis
- Vomiting
- Nausea Post Chemotherapy
- Nausea
- Chemotherapy-induced Nausea and Vomiting

## Interventions

- **DRUG:** Olanzapine
- **DRUG:** Aprepitant Pill
- **DRUG:** Ondansetron
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT03478605
- **Lead sponsor:** Blokhin's Russian Cancer Research Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-05-25
- **Primary completion:** 2019-05-25
- **Final completion:** 2019-06-01
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2018-07-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03478605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03478605, "Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea & Vomiting (CINV) Prophylaxis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03478605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*